Search

Displaying results 3331 - 3340 of 5506 in total
  1. Drug

    EHT899

    go.drugbank.com/drugs/DB05108
    Experimental

    It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.

  2. Drug

    Imidafenacin

    go.drugbank.com/drugs/DB09262
    Investigational

    It is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical. … It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder.

  3. Drug

    Tifuvirtide

    go.drugbank.com/drugs/DB05413
    Investigational

    It has received fast-track designation from the FDA and is in Phase I/II clinical testing.

  4. Drug

    Cefmenoxime

    go.drugbank.com/drugs/DB00267
    Approved

    It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria.

    Synonyms: (6R,7R)-7-((Z)-2-(2-Amino-4-thiazolyl)-2-methoxyiminoacetamido)-3-((1-methyl-1H-5-tetraazolylthio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-2-carbonsaeure
  5. Drug

    Zaleplon

    go.drugbank.com/drugs/DB00962
    ApprovedIllicit

    It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines.

  6. Drug

    Antipyrine

    go.drugbank.com/drugs/DB01435
    Approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)

  7. Drug

    Barbital

    go.drugbank.com/drugs/DB01483
    ExperimentalIllicit

    A long-acting barbiturate that depresses most metabolic processes at high doses. It is used as a hypnotic and sedative and may induce dependence.

  8. Drug

    Dalfampridine

    go.drugbank.com/drugs/DB06637
    ApprovedInvestigational

    Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.

  9. Drug

    Pipendoxifene

    go.drugbank.com/drugs/DB05414
    Investigational

    ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer.

  10. Drug

    Factor XIII (human)

    go.drugbank.com/drugs/DB12909
    ApprovedInvestigational

    When activated by thrombin at the site of injury, the FXIII pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit.